1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,370 | 1,430 | 01.12. | |
| 1,370 | 1,430 | 01.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.11. | MaxCyte stellt auf Stephens-Konferenz Neuausrichtung | 1 | Investing.com Deutsch | ||
| 13.11. | MAXCYTE, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11. | MaxCyte reports Q3 results | 1 | Seeking Alpha | ||
| 13.11. | MaxCyte outlines $17M-$19M annualized savings through restructuring while reiterating SPL revenue guidance | 1 | Seeking Alpha | ||
| 12.11. | MaxCyte CFO to step down in first half of 2026 | 2 | Seeking Alpha | ||
| 12.11. | MaxCyte CFO Douglas Swirsky to step down in first half of 2026 | 4 | Investing.com | ||
| 12.11. | MaxCyte, Inc: MaxCyte Announces Planned CFO Transition in 2026 | 84 | GlobeNewswire (Europe) | ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development... ► Artikel lesen | |
| 11.11. | Insights into MaxCyte's Upcoming Earnings | 1 | Benzinga.com | ||
| MAXCYTE Aktie jetzt für 0€ handeln | |||||
| 05.11. | MAXCYTE, INC. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | MaxCyte reports Q3 results | 1 | Seeking Alpha | ||
| 05.11. | MaxCyte, Inc: MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance | 150 | GlobeNewswire (Europe) | MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November... ► Artikel lesen | |
| 08.10. | MaxCyte, Inc: MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 | 3 | GlobeNewswire (USA) | ||
| 06.10. | MaxCyte, Inc: MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors | 281 | GlobeNewswire (Europe) | ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and... ► Artikel lesen | |
| 22.09. | MaxCyte announces 34% workforce reduction to cut costs | 1 | Seeking Alpha | ||
| 22.09. | MAXCYTE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.09. | MaxCyte, Inc: MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability | 204 | GlobeNewswire (Europe) | ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development... ► Artikel lesen | |
| 26.08. | MAXCYTE, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 11.08. | MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns | 11 | Investing.com | ||
| 07.08. | MaxCyte stock downgraded by William Blair to Market Perform on weak guidance | 2 | Investing.com | ||
| 07.08. | MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation | 1 | Seeking Alpha |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,371 | +0,62 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease | RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted... ► Artikel lesen | |
| IMMATICS | 8,930 | +0,96 % | Immatics Announces Third Quarter 2025 Financial Results and Business Update | Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will... ► Artikel lesen | |
| ALDEYRA | 4,661 | +3,17 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| MEDIFAST | 9,320 | +0,84 % | Medifast's Q3 Loss Wider Than Expected, Sales Decline 36% Y/Y | ||
| PHARMING | 1,381 | -0,36 % | Pharming Group N.V.: Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow | Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,132 | +3,00 % | Coherus Oncology, Inc.: Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer | - Responsible for Corporate Development, Investor Relations, Government Affairs - REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 25,600 | -1,54 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three... ► Artikel lesen | |
| ARMATA PHARMACEUTICALS | 6,050 | +4,31 % | Armata Pharmaceuticals, Inc. - 8-K, Current Report | ||
| INNOVIVA | 18,100 | -3,21 % | Innoviva Specialty Therapeutics, Inc.: FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 | FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update | NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 5,880 | -2,97 % | SIGA Technologies - Fundamentals intact amid several moving parts | Q325 was a quieter quarter for SIGA following strong Q2 sales, although this was not unexpected given its contract-driven model and inherent revenue lumpiness. No product sales were recorded, with total... ► Artikel lesen | |
| DBV TECHNOLOGIES | 2,295 | -0,22 % | DBV Technologies S.A.: DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years | Châtillon, France, November 11, 2025
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Company... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 16,400 | -0,61 % | Syndax Pharmaceuticals, Inc.: Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update | - $45.9 million in total revenue, representing 21% growth over 2Q25 - - $32.0 million Revuforj® (revumenib) net revenue; total Revuforj prescriptions in 3Q25 increased 25% over 2Q25, highlighting... ► Artikel lesen | |
| LIQUIDIA | 27,940 | +1,23 % | Liquidia Technologies, Inc.: Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Recorded $51.7 million in net product sales of YUTREPIA as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and... ► Artikel lesen | |
| MATINAS BIOPHARMA | 0,770 | +4,05 % | Finanzchef von Matinas BioPharma kündigt Rücktritt an |
MAXCYTE INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,530 Euro und damit +9,29 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAXCYTE INC finden Sie auf Wallstreet Online.